Search

Your search keyword '"Nobuhiro Yoshijima"' showing total 2 results
Start Over Author "Nobuhiro Yoshijima" Journal catheterization and cardiovascular interventions : official journal of the society for cardiac angiographyinterventionsreferences
2 results on '"Nobuhiro Yoshijima"'

1. Transcatheter aortic valve replacement with Evolut R versus Sapien 3 in Japanese patients with a small aortic annulus: The OCEAN-TAVI registry

Author

Kentaro Hayashida, Keiichi Fukuda, Masahiro Yamawaki, Ocean-Tavi Investigators, Yusuke Watanabe, Masanori Yamamoto, Hideyuki Shimizu, Hiroshi Ueno, Toru Naganuma, Hiromu Hase, Futoshi Yamanaka, Nobuhiro Yoshijima, Kensuke Takagi, Ryo Yanagisawa, Minoru Tabata, Makoto Tanaka, Hikaru Tsuruta, Shinichi Shirai, Norio Tada, and Kazuki Mizutani

Subjects
medicine.medical_specialty, medicine.medical_treatment, Hemodynamics, Regurgitation (circulation), 030204 cardiovascular system & hematology, Prosthesis Design, Transcatheter Aortic Valve Replacement, 03 medical and health sciences, 0302 clinical medicine, Valve replacement, Japan, Interquartile range, Internal medicine, medicine, Humans, Radiology, Nuclear Medicine and imaging, 030212 general & internal medicine, Cardiac skeleton, Registries, Body surface area, business.industry, General Medicine, Aortic Valve Stenosis, Treatment Outcome, Aortic Valve, Heart Valve Prosthesis, Cohort, Propensity score matching, Cardiology, Cardiology and Cardiovascular Medicine, business
Abstract

OBJECTIVES To compare safety, efficacy, and hemodynamics of transfemoral transcatheter aortic valve replacement (TAVR) using self-expanding and balloon-expandable transcatheter heart valves (THVs) in patients with a small aortic annulus. BACKGROUND Few studies have directly compared TAVR outcomes using third-generation THVs, focusing on patients with small aortic annuli. METHODS In a multicenter TAVR registry, we analyzed data from 576 patients with a small annulus and who underwent transfemoral TAVR using third-generation THVs. Propensity score matching was used to adjust baseline clinical characteristics. RESULTS The device success rate in the overall cohort was 92.0% (Evolut R: 92.1% vs. Sapien 3:92.0%, p = 0.96). One year after TAVR, patients treated with Evolut R maintained a lower mean pressure gradient (mPG) and a higher indexed effective orifice area (iEOA) in the matched cohort {mPG: 9.0 [interquartile range (IQR): 6.0-11.9] vs. 12.0 [IQR: 9.9-16.3] mmHg, p

Published
2020

2. Update on the clinical impact of mild aortic regurgitation after transcatheter aortic valve implantation: Insights from the Japanese multicenter OCEAN-TAVI registry

Author

Yusuke Watanabe, Hiromu Hase, Shinichi Shirai, Keiichi Fukuda, Ocean-Tavi Investigators, Kentaro Hayashida, Akihiro Higashimori, Norio Tada, Ryo Yanagisawa, Hideyuki Shimizu, Masanori Yamamoto, Kazuki Mizutani, Kensuke Takagi, Motoharu Araki, Hikaru Tsuruta, Toru Naganuma, Futoshi Yamanaka, Nobuhiro Yoshijima, Minoru Tabata, Hiroshi Ueno, and Makoto Tanaka

Subjects
Male, medicine.medical_specialty, Time Factors, Aortic Valve Insufficiency, Regurgitation (circulation), 030204 cardiovascular system & hematology, Left ventricular hypertrophy, Patient Readmission, Risk Assessment, Severity of Illness Index, Ventricular Function, Left, Transcatheter Aortic Valve Replacement, 03 medical and health sciences, Ventricular Dysfunction, Left, 0302 clinical medicine, Japan, Risk Factors, Internal medicine, Medicine, Humans, Radiology, Nuclear Medicine and imaging, Cumulative incidence, cardiovascular diseases, 030212 general & internal medicine, Registries, Retrospective Studies, Aged, 80 and over, Bioprosthesis, Ejection fraction, Ventricular Remodeling, business.industry, Incidence (epidemiology), Hazard ratio, Hemodynamics, General Medicine, Aortic Valve Stenosis, medicine.disease, Confidence interval, Treatment Outcome, Heart failure, Aortic Valve, Heart Valve Prosthesis, Cardiology, Female, Hypertrophy, Left Ventricular, Cardiology and Cardiovascular Medicine, business
Abstract

Objectives This study aimed to compare the clinical impact of mild postprocedural aortic regurgitation (post-AR) to that of none-trivial post-AR after transcatheter aortic valve implantation (TAVI) and to identify the vulnerability factors to mild post-AR. Background Moderate-severe post-AR, associated with increased mortality, is an important issue. However, the clinical impact of mild post-AR remains controversial. Methods and results We analyzed data from 1,572 consecutive patients (1,026 of none-trivial post-AR and 546 of mild post-AR) obtained from the Optimized transCathEter vAlvular Intervention (OCEAN-TAVI) Japanese multicenter registry. We evaluated the 1-year cumulative cardiovascular death and re-hospitalization rates for heart failure (HF) after TAVI according to the degree of post-AR. Kaplan-Meier curves showed no significant difference between "none-trivial post-AR" and "mild post-AR" in terms of cardiovascular death, but a significant difference was noted in the cumulative incidence of re-hospitalization for HF between the two groups (hazard ratio 1.57, 95% confidence interval 1.02-2.41, p = .04). In the stratified analysis, only in patients with not more than 50% of left ventricular ejection fraction (LVEF), concentric left ventricular hypertrophy (LVH), and none-trivial pre-procedural aortic regurgitation (pre-AR), mild post-AR resulted in a higher incidence of re-hospitalization for HF. Conclusions In this study, the clinical impact of mild post-AR compared to none-trivial post-AR tended to be augmented in the presence of reduced LVEF, concentric LVH, and none-trivial pre-AR. Pre-procedure echocardiographic findings including LVEF, left ventricular geometry, and pre-AR may help to judge the necessity of postdilatation in case of mild post-AR just after the bioprosthesis deployment.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results